6-pentafluoroethyl-2,2-bis(fluoromethyl)-2H-1-benzopyran-4-carboxylic acid ethyl ester | 152661-73-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 6-pentafluoroethyl-2,2-bis(fluoromethyl)-2H-1-benzopyran-4-carboxylic acid ethyl ester
• 英文别名: 2,2-bis(fluoromethyl)-6-(pentafluoroethyl)-2H-1-benzopyran-4-carboxylic acid ethyl ester；ethyl 6-pentafluoroethyl-2,2-bisfluoromethyl-2H-1-benzopyran-4-carboxylate；6-pentafluoroethyl-2,2-bisfluoromethyl-2H-1-benzopyran-4-carboxylic acid ethyl ester；ethyl 2,2-bis(fluoromethyl)-6-(1,1,2,2,2-pentafluoroethyl)chromene-4-carboxylate
• CAS: 152661-73-9
• 化学式: C₁₆H₁₃F₇O₃
• 分子量: 386.266
• InChiKey: RUCDARGCCOZMHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  6-pentafluoroethyl-2,2-bis(fluoromethyl)-2H-1-benzopyran-4-carboxylic acid ethyl ester 生成 N-(2-Cyanoethyl)-6-pentafluoroethyl-2,2-bis(fluoromethyl)-2H-1-benzopyran-4-carboxamide
  参考文献：
  名称：

  Remedies for peripheral circulation disturbances

  摘要：

  本发明的目的是为外周血管疾病提供新型治疗药物。 本发明提供了包含一种通式（1）的苯并吡喃或苯并噁嗪衍生物的药物组合物： 其中； R1代表氢原子、较低的烷基或芳基，或R1直接与Q或R11结合形成单键； R2代表取代或未取代的氨基、饱和或不饱和的杂环基、A—O—或—C(═X)Y； Q代表═N—、N+—O−或C(R11)R12； R3和R4各自代表氢原子、较低的烷基或具有卤原子或较低的烷氧基等取代基的取代的较低烷基，R5和R6各自代表氢原子、卤原子、较低的烷基、较低的卤代烷基或类似物；以及一种药学上可接受的载体。

  公开号：

  US06248777B1
• 作为产物：
  描述：

  4-bromo-2,2-bis(fluoromethyl)-6-nitro-2H-1-benzopyran 在 palladium diacetate 、 Raney Ni (W-1) copper(l) iodide 、 硫酸 、 氢气 、 potassium acetate 、 三苯基膦 、 potassium iodide 、 sodium nitrite 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 11.0h， 生成 6-pentafluoroethyl-2,2-bis(fluoromethyl)-2H-1-benzopyran-4-carboxylic acid ethyl ester
  参考文献：
  名称：

  6-Substituted 2,2-Bis(fluoromethyl)-benzopyran-4-carboxamide K + channel openers

  摘要：

  In the course of our study to find an ideal antihypertensive potassium channel opener (KCO), N-(2-cyanoethyl)-2,2 bis(fluoromethyl)-6-pentafluoroethyl-2H-1-benzopyran-4-carboxamide (13f, KC-515) showed a highly potent, slow and long-lasting antihypertensive effect with reduced reflex tachycardia, together with the beneficial effects of KCO such as improvement in lipid metabolism. These profiles identify KC-515 as a potential candidate. In conscious spontaneously hypertensive rats (SHR), the onset of the hypotensive effect of KC-515 (13f) was gradual and the maximum response was attained at around 6 h after dosing. The duration of action was over 18 h for 0.1 mg/kg. When administered to Zucker rats for 2 weeks with 0.03-0.3 mg/kg po range in the antihypertensive doses in hypertensive rat models, KC-515 (13f) significantly and dose-dependently reduced serum triglycerides to less than 70% of control without affecting total cholesterol. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00064-x

文献信息

• Benzopyran derivatives
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：US05646308A1

  公开（公告）日：1997-07-08

  Benzopyran derivatives represented by formula (I): ##STR1## wherein X represents .dbd.O, .dbd.S, .dbd.N--Z, etc. (Z represents a lower alkyl group, etc.); Y represents a substituted amino group, an alkoxy group, an alkylthio group, etc., and R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 each represents a hydrogen atom, a lower alkyl group, etc, are disclosed. The benzopyran derivative exhibit K.sup.+ channel opening activities and are widely applicable as antiasthmatics, antiepileptics, and the like.

  公式（I）所代表的苯并吡喃衍生物：其中X代表.dbd.O，.dbd.S，.dbd.N--Z等（Z代表较低的烷基基团等）；Y代表取代氨基团，烷氧基团，烷基硫基团等；R.sub.1，R.sub.2，R.sub.3，R.sub.4和R.sub.5分别代表氢原子，较低的烷基基团等。这些苯并吡喃衍生物表现出K.sup.+通道开放活性，并广泛应用于抗哮喘药物，抗癫痫药物等。
• N-(2-cyanoethyl)-6-fluoroalkyl-2h-1-benzopyran derivatives
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：US05646310A1

  公开（公告）日：1997-07-08

  Described herein are benzopyran derivatives represented by the formula: ##STR1## wherein R, X and Y represent any of the following combinations: ______________________________________ R X Y ______________________________________ C.sub.2 F.sub.5 O H C.sub.2 F.sub.5 S H CF.sub.3 S F C.sub.2 F.sub.5 S F C.sub.3 F.sub.7 S F ______________________________________ PAL and pharmaceutically acceptable salts thereof. These compounds have an excellent potassium channel activity and are also excellent from the aspect of safety.

  本文描述了由以下公式表示的苯并吡喃衍生物：##STR1## 其中R、X和Y代表以下任意组合之一： ______________________________________ R X Y ______________________________________ C.sub.2 F.sub.5 O H C.sub.2 F.sub.5 S H CF.sub.3 S F C.sub.2 F.sub.5 S F C.sub.3 F.sub.7 S F ______________________________________ PAL及其药学上可接受的盐。这些化合物具有优异的钾通道活性，并且从安全性方面也表现出色。
• NOVEL BENZOPYRAN DERIVATIVE
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP0632033A1

  公开（公告）日：1995-01-04

  A benzopyran derivative represented by general formula (I), which has a K⁺ channel activating function and thus can be widely applied as antiasthmatic, antiepileptic, and so forth. In formula (I), R₁ represents hydrogen or hydroxy; R₂ and R₃ represent each lower alkyl, etc.; R₄ and R₅ represent each hydrogen, lower haloalkyl, halogeno, nitro, etc.; X represents =O, =S, = N-CN, etc.; and Y represents hydroxy, substituted amino, etc.

  一种由通式(I)代表的苯并吡喃衍生物，它具有激活 K⁺通道的功能，因此可广泛应用于抗哮喘、抗癫痫等方面。在式（I）中，R₁ 代表氢或羟基；R₂ 和 R₃ 分别代表低级烷基等；R₄ 和 R₅ 分别代表氢、低级卤代烷基、卤代、硝基等；X 代表＝O、＝S、＝N-CN 等；Y 代表羟基、取代氨基等。
• BENZOPYRAN DERIVATIVE
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：EP0702952A1

  公开（公告）日：1996-03-27

  A benzopyran derivative represented by general formula (I) and a pharmaceutically acceptable salt thereof, whrein R, X and Y represent together any of the combinations represented by (A). These compounds are excellent in the potassium channel activity and also in safety.

  通式（I）代表的苯并吡喃衍生物及其药学上可接受的盐，其中 R、X 和 Y 共同代表（A）所代表的任何组合。这些化合物具有优异的钾通道活性和安全性。
• REMEDIES FOR PERIPHERAL CIRCULATION DISTURBANCES
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP0995438A1

  公开（公告）日：2000-04-26

  It is an object of the present invention to provide novel therapeutic agents for peripheral vascular disease. The present invention provides pharmaceutical compositions comprising a benzopyran or benzoxazine derivative of the general formula (1): wherein; R1 represents a hydrogen atom, a lower alkyl group or an aryl group, or R1 directly couples with Q or R11 to form a single bond; R2 represents a substituted or unsubstituted amino group, a saturated or unsaturated heterocyclic group, A-O- or -C(=X)Y; Q represents =N-, N+-O- or C(R11)R12; R3 and R4 each represent a hydrogen atom, a lower alkyl group or a substituted lower alkyl group having a halogen atom or a lower alkoxy group as a substituent or the like; and R5 and R6 each represent a hydrogen atom, a halogen atom, a lower alkyl group, a lower haloalkyl group or the like; and a pharmaceutically acceptable carrier.

  本发明的目的是提供治疗外周血管疾病的新型治疗剂。 本发明提供了包含通式（1）的苯并吡喃或苯并噁嗪衍生物的药物组合物： 其中 R1 代表氢原子、低级烷基或芳基，或 R1 直接与 Q 或 R11 偶联形成单键； R2 代表取代或未取代的氨基、饱和或不饱和杂环基、A-O- 或-C(=X)Y； Q 代表 =N-、N+-O- 或 C(R11)R12； R3 和 R4 分别代表氢原子、低级烷基或以卤原子或低级烷氧基为取代基的取代低级烷基或类似基团；以及 R5 和 R6 分别代表氢原子、卤原子、低级烷基、低级卤代烷基或类似基团； 以及药学上可接受的载体。